CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013		Apr. 01, 2012
Operating Activities
Net income before allocation to noncontrolling interests	$ 2,765		$ 1,803
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	1,774		2,221
Share-based compensation expense	189		130
Gain associated with the transfer of certain product rights to an equity-method investment	(490)		0
Asset write-offs and impairment charges	513		650
Deferred taxes from continuing operations	927		(396)
Deferred taxes from discontinued operations	0		(8)
Benefit plan contributions (in excess of)/less than expense	71		(65)
Other non-cash adjustments, net	(115)		(28)
Other changes in assets and liabilities, net of acquisitions and divestitures	(3,393)		(1,533)
Net cash provided by operating activities	2,241		2,774
Investing Activities
Purchases of property, plant and equipment	(202)		(254)
Purchases of short-term investments	(10,742)		(6,344)
Proceeds from redemptions and sales of short-term investments	6,386		8,119
Net (purchases of)/proceeds from redemptions and sales of short-term investments with original maturities of 90 days or less	(5,596)		623
Purchases of long-term investments	(2,246)		(1,184)
Proceeds from redemptions and sales of long-term investments	1,444		302
Acquisitions, net of cash acquired	0		(782)
Other investing activities	26		(29)
Net cash provided by/(used in) investing activities	(10,930)		451
Financing Activities
Proceeds from short-term borrowings	0		1,561
Net proceeds from/(payments on) short-term borrowings with original maturities of 90 days or less	3,485		(1,791)
Proceeds from issuance of long-term debt	2,624	[1]	0	[1]
Principal payments on long-term debt	(2)		(3)
Purchases of common stock	(4,626)		(1,659)
Cash dividends paid	(1,735)		(1,650)
Proceeds from exercise of stock options and other financing activities	688		35
Net cash provided by/(used in) financing activities	434		(3,507)
Effect of exchange-rate changes on cash and cash equivalents	0		34
Net decrease in cash and cash equivalents	(8,255)		(248)
Cash and cash equivalents, beginning	10,389		3,182
Cash and cash equivalents, end	2,134		2,934
Non-cash transactions:
Exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012	992	[2]	0	[2]
Exchange of Zoetis common stock for the retirement of Pfizer commercial paper issued in 2013	2,479	[2]	0	[2]
Transfer of certain product rights to an equity-method investment(c)	1,233	[3]	0	[3]
Cash paid during the period for:
Cash paid during the period for income taxes	554		451
Cash paid during the period for interest	$ 433		$ 508

[1] Represents the issuance of senior notes by Zoetis, our Animal Health subsidiary, net of the non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 7D. Financial Instruments: Long-Term Debt.

[2] See Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Divestitures.

[3] See Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment.